Uncovering Anti-Obesity Candidates from Robusta Green Coffee: In Silico Evaluation of Bioactive Compounds Targeting PPAR-α

Bintang Satrio Mahardika; Viona Algesia Fiola Putri; Yolla Adellia Putri; Jasimah Jasimah; Kevin Gabriel; Agus Rusdin; Dhania Novitasari

doi:10.70392/jpns.v2i3.40

Authors

Bintang Satrio Mahardika Faculty of Pharmacy, Universitas Padjadjaran Author
Viona Algesia Fiola Putri Faculty of Pharmacy, Universitas Padjadjaran Author
Yolla Adellia Putri Faculty of Pharmacy, Universitas Padjadjaran Author
Jasimah Jasimah Faculty of Pharmacy, Universitas Padjadjaran Author
Kevin Gabriel Faculty of Pharmacy, Universitas Padjadjaran Author
Agus Rusdin Poltekkes Kemenkes Bandung Author
Dhania Novitasari Faculty of Pharmacy, Universitas Padjadjaran Author

DOI:

https://doi.org/10.70392/jpns.v2i3.40

Keywords:

Obesity, PPAR-α, Coffea canephora, Molecular Docking

Abstract

Obesity arises from a chronic imbalance between energy intake and expenditure, leading to excessive accumulation of body fat. Peroxisome proliferator-activated receptor-alpha (PPARα) plays a key regulatory role in lipid metabolism, particularly in reducing the de novo synthesis of fatty acids. Robusta coffee has been widely consumed as part of the lifestyle, yet scientific evidence for its pharmacological effects is limited. This study aimed to evaluate the molecular interactions between secondary metabolites from Green Bean Coffee Robusta (Coffea canephora P.) and PPARα using in silico approaches. The workflow included screening compounds from C. canephora based on Lipinski’s Rule of Five (RO5) and ADMET predictions, followed by pharmacophore modelling and molecular docking simulations using AutoDock against PPARα (PDB ID: 2P54). All the bioactive constituents in C. canephora met the requirements of RO5, and several metabolites were assessed based on their pharmacokinetic profile and toxicology prediction. Further molecular docking analysis identified 4-ethyl-2-methoxyphenol as the most promising anti-obesity candidate, demonstrating the lowest binding energy (-4.58 kcal/mol) and an inhibition constant of 440.47 µM. The compound formed key hydrogen bonds with amino acid residues ALA333, THR279, CYS276, and CYS275. These findings suggest that 4-ethyl-2-methoxyphenol from Green Bean Coffee Robusta exhibits potential as an anti-obesity agent through its interaction with the PPARα receptor. Further in vitro and in vivo studies are required to validate its pharmacological effects.

References

Kementerian Kesehatan Republik Indonesia. Hasil Riset Kesehatan Dasar. Kementerian Kesehatan Republik Indonesia. 2018.

Kementerian Kesehatan Republik Indonesia. Pedoman Umum Pengendalian Obesitas. Direktorat Pengendalian Penyakit Tidak Menular. 2015.

Engin, A. The definition and prevalence of obesity and metabolic syndrome. Adv Exp Med Biol. 2017, 960, 1–17. https://doi.org/10.1007/978-3-319-48382-5_1.

Blüher, M. Obesity: Global epidemiology and pathogenesis. Nat Rev Endocrinol. 2019, 15(5), 288–298. https://doi.org/10.1038/s41574-019-0176-8.

World Health Organization (WHO). Obesity and overweight: Key facts. World Health Organization. 2021. Available from: https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight.

Li, W., Liu, Q., Deng, X., Chen, Y., Liu, S., Story, M. Association between obesity and puberty timing: A systematic review and meta-analysis. Int J Environ Res Public Health. 2017, 14(10), 1266. https://doi.org/10.3390/ijerph14101266.

Wilding, J.P.H., Batterham, R.L., Calanna, S., Davies, M., Van Gaal, L.F., Lingvay, I., McGowan, B.M., Rosenstock, J., Tran, M.T.D., Wadden, T.A., Wharton, S., Yokote, K., Zeuthen, N., Kushner, R.F., STEP 1 Study Group. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183.

Khera, R., Murad, M.H., Chandar, A.K., Dulai, P.S., Wang, Z., Prokop, L.J., Loomba, R., Camilleri, M., Singh, S. Association of pharmacological treatments for obesity with weight loss and adverse events: A systematic review and meta-analysis. JAMA. 2016, 315(22), 2424–2434. https://doi.org/10.1001/jama.2016.7602.

Bansal, A.B., Patel, P., Al Khalili, Y. Orlistat. StatPearls. 2024. StatPearls Publishing.

Mauer, Y., Parker, M., Kashyap, S.R. Antiobesity drug therapy: An individualized and comprehensive approach. Cleve Clin J Med. 2021, 88(8), 440–448. https://doi.org/10.3949/ccjm.88a.20080.

Purnama, D.J.A. Potensi dan mekanisme kerja berbagai tanaman herbal dalam membantu mengatasi obesitas. Prosiding Workshop dan Seminar Nasional Farmasi. 2022, 1(1).

Kanchanasurakit, S., Saokaew, S., Phisalprapa, P., Duangjai, A. Chlorogenic acid in green bean coffee on body weight: A systematic review and meta-analysis of randomized controlled trials. Syst Rev. 2023, 12(1), 163. https://doi.org/10.1186/s13643-023-02311-4.

Pujasari, N.L.W.S., Astuti, N.M.W. Potensi biji kopi hijau (Green Bean Coffee) sebagai suplemen penurun berat badan. Prosiding Workshop dan Seminar Nasional Farmasi. 2022, 1(1).

Harpaz, E., Tamir, S., Weinstein, A., Weinstein, Y. The effect of caffeine on energy balance. J Basic Clin Physiol Pharmacol. 2017, 28(1), 1–10. https://doi.org/10.1515/jbcpp-2016-0090.

Hafsah, H., Iriawati, I., Syamsudin, T.S. Dataset of volatile compounds from flowers and secondary metabolites from the skin pulp, green beans, and peaberry green beans of robusta coffee. Data Brief. 2020, 29, 105219.

da Silva, M.R., Jelley, R.E., Carneiro, R.L., Fedrizzi, B., Weber, C.C., Funari, C.S. Green solvents for the selective extraction of bioactive compounds from by-products of the coffee production chain. Innov Food Sci Emerg Technol. 2023, 86, 103365.

Xiang, J., Wu, M., Wang, J., Lin, M., Sun, M., Li, X., Xing, R., Guo, R., Gu, J., Lyu, T., Wang, L., Shi, X. Pharmacokinetics, bioavailability, and plasma protein binding study of glytrexate, a novel multitarget antifolate. Front Pharmacol. 2022, 13, 1001308. https://doi.org/10.3389/fphar.2022.1001308.

Nabi, A.E., Lee, C.Y., Kim, S.J. A review of blood–brain barrier permeability prediction models. WIREs Comput Mol Sci. 2025, 15(3), e1642. https://doi.org/10.1002/minf.202400325.

Ancuceanu, R., Dinu, M., Anghel, I.F., Purcărea, A. In silico ADME methods used in the evaluation of natural compounds: Advances and best practices. Pharmaceutics. 2025, 17(8), 1002. https://doi.org/10.3390/pharmaceutics17081002.

Guedes, I.A., de Magalhães, C.S., Dardenne, L.E. Empirical scoring functions for structure-based virtual screening: Strengths and limitations. Front Pharmacol. 2018, 9, 1089. https://doi.org/10.3389/fphar.2018.01089.

Adediwura, V.A., Koirala, K., Do, H.N., Wang, J., Miao, Y. Understanding the impact of binding free energy and kinetics calculations in modern drug discovery. Expert Opin Drug Discov. 2024, 19(6), 671–682. https://doi.org/10.1080/17460441.2024.2349149.

Bougarne, N., Weyers, B., Desmet, S.J., Deckers, J., Ray, D.W., Staels, B., De Bosscher, K. Molecular actions of PPARα in lipid metabolism and inflammation. Endocr Rev. 2018, 39(5), 760–802. https://doi.org/10.1210/er.2018-00064.

Lin, Y., Wang, Y., Li, P.-F. PPARα: An emerging target of metabolic syndrome, neurodegenerative, and cardiovascular diseases. Front Endocrinol. 2022, 13, 1074911. https://doi.org/10.3389/fendo.2022.1074911.